JPWO2020245382A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020245382A5 JPWO2020245382A5 JP2021571766A JP2021571766A JPWO2020245382A5 JP WO2020245382 A5 JPWO2020245382 A5 JP WO2020245382A5 JP 2021571766 A JP2021571766 A JP 2021571766A JP 2021571766 A JP2021571766 A JP 2021571766A JP WO2020245382 A5 JPWO2020245382 A5 JP WO2020245382A5
- Authority
- JP
- Japan
- Prior art keywords
- eosinophilic
- medicament according
- pharmaceutical compositions
- administered
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000019097 eosinophilic gastrointestinal disease Diseases 0.000 claims 4
- 230000002327 eosinophilic effect Effects 0.000 claims 3
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 238000009098 adjuvant therapy Methods 0.000 claims 2
- 206010057271 eosinophilic colitis Diseases 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 229950010984 irsogladine Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- PJLVTVAIERNDEQ-BTJKTKAUSA-N Irsogladine maleate Chemical group OC(=O)\C=C/C(O)=O.NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 PJLVTVAIERNDEQ-BTJKTKAUSA-N 0.000 claims 1
- 208000036633 Jejunitis Diseases 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 229960004314 bilastine Drugs 0.000 claims 1
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013864 duodenitis Diseases 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 229960001971 ebastine Drugs 0.000 claims 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims 1
- 201000001561 eosinophilic gastritis Diseases 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- 229960001596 famotidine Drugs 0.000 claims 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960003174 lansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 229960005108 mepolizumab Drugs 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229960005249 misoprostol Drugs 0.000 claims 1
- 229960005127 montelukast Drugs 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 229960005019 pantoprazole Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- 229960000620 ranitidine Drugs 0.000 claims 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 1
- 229950004535 rebamipide Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382478 | 2019-06-07 | ||
| EP19382478.6 | 2019-06-07 | ||
| PCT/EP2020/065660 WO2020245382A1 (en) | 2019-06-07 | 2020-06-05 | Irsogladine for the treatment of eosinophilic gastrointestinal diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535400A JP2022535400A (ja) | 2022-08-08 |
| JPWO2020245382A5 true JPWO2020245382A5 (enrdf_load_html_response) | 2023-06-09 |
Family
ID=66821162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571766A Pending JP2022535400A (ja) | 2019-06-07 | 2020-06-05 | 好酸球性消化管疾患の処置のためのイルソグラジン |
Country Status (8)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200015511A (ko) * | 2017-05-05 | 2020-02-12 | 알라코스 인크. | 염증성 위장 장애를 치료하기 위한 방법 및 조성물 |
-
2020
- 2020-06-05 CA CA3142450A patent/CA3142450A1/en active Pending
- 2020-06-05 WO PCT/EP2020/065660 patent/WO2020245382A1/en not_active Ceased
- 2020-06-05 EP EP20730049.2A patent/EP3980020B1/en active Active
- 2020-06-05 AU AU2020286764A patent/AU2020286764A1/en active Pending
- 2020-06-05 US US17/616,614 patent/US20220226333A1/en active Pending
- 2020-06-05 KR KR1020217040553A patent/KR20220018975A/ko not_active Ceased
- 2020-06-05 JP JP2021571766A patent/JP2022535400A/ja active Pending
- 2020-06-05 ES ES20730049T patent/ES2965508T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9877971B2 (en) | Soft lozenges comprising corticosteroids | |
| ES2977953T3 (es) | Comprimido | |
| NZ511999A (en) | Pharmaceutical formulation comprising a H+,K+-ATPase inhibitor and a gastric antisecretory prostaglandin analogue | |
| MXPA06000873A (es) | Formulacion de liberacion inmediata de composiciones farmaceuticas labiles a acido. | |
| JP6364406B2 (ja) | 口腔内崩壊錠 | |
| RU2227033C2 (ru) | Тауролидин и/или таурултам при лечении инфекционной язвенной болезни или инфекционного гастрита | |
| WO2012074110A1 (ja) | 口腔内崩壊錠 | |
| DE60237363D1 (de) | Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden | |
| JPWO2007074910A1 (ja) | 放出制御固形製剤 | |
| US20040131676A1 (en) | Dosage forms containing a PPI, NSAID, and buffer | |
| JP2002525266A5 (enrdf_load_html_response) | ||
| US12239737B2 (en) | Oral rapamycin nanoparticle preparations and use | |
| CZ298799B6 (cs) | Použití inhibitoru H+, K+ - ATPázy pro lécbu nazálních polypu | |
| JP2008505139A (ja) | 悪心および嘔吐の処置における置換２−チオ−３，５−ジシアノ−４−フェニル−６−アミノピリジン類の使用 | |
| JPWO2020245382A5 (enrdf_load_html_response) | ||
| CN104814964B (zh) | 一种抗胃幽门螺旋杆菌的药物组合物、制备方法及其应用 | |
| US9867834B2 (en) | Non-systemic topical compositions comprising corticosteroids | |
| US20040258621A1 (en) | Method of treating snoring and other obstructive breathing disorders | |
| EP3980020B1 (en) | Irsogladine for the treatment of eosinophilic gastrointestinal diseases | |
| US20180263917A1 (en) | Single solid oral dosage forms for treating helicobacter pylori infection and duodenal ulcer disease | |
| KR101460828B1 (ko) | 두개골 외상의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도 | |
| RU2007120522A (ru) | Использование кортикостероида в сочетании с диуретиком и антацидом для лечения стеноза сосудов и предупреждения рестеноза сосудов | |
| ES2306905T3 (es) | Utilizacion del tenatoprazol para el tratamiento del reflujo gastroesofagico. | |
| JP2005154431A (ja) | 固形製剤 | |
| WO2011136750A1 (en) | Pharmaceutical compositions inducing synergistic effect |